Stay updated with breaking news from Zymework Amendment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce that the Company’s securityholders have approved its p...
Redomicile anticipated to enhance long-term value for securityholders, provide opportunities for increased value of Zymeworks common shares, and better position the Company for future growthZymeworks Board recommends that Zymeworks securityholders vote FOR the Redomicile resolutionTo vote, contact Kingsdale Advisors...
Redomicile anticipated to enhance long-term value for securityholders, provide opportunities for increased value of Zymeworks common shares, and better position the Company for future... | September 8, 2022
Enhances alignment with US shareholder base and other peer biotechnology companiesPositions company for growth while helping to reduce complexity and certain administrative costsThe Company’s name, brand, and ticker symbol to remain unchangedVANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (“Zy...